The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now offering ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to go through early next week. On Friday, private equity firms Carlyle and SK ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) of $6.84 per share in ...

David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing The transaction is expected to close in the first half of 2025 At the closing of the ...

A consortium consisting of the Carlyle Group, SK Capital Partners, LP and Beacon Parent Holdings, L. P. extended the deadline for concluding an agreement to acquire the American biotech company ...

WASHINGTON & NEW YORK - Investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, along with Beacon Parent Holdings, L.P., have successfully completed their tender offer to acquire all ...

Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR SOMERVILLE, ...